Samsung Biologics to Participate in BioJapan 2025, Showcasing Innovative Biopharmaceutical Capabilities and Strengthening Global Partnerships
Samsung Biologics has officially announced its participation in BioJapan 2025, Asia’s premier biopharmaceutical partnering event, which will be held from October 8 to 10, 2025, in Yokohama, Japan. The company’s involvement this year carries special significance as it prepares to highlight its growing global footprint, its expanding portfolio of biopharmaceutical services, and its commitment to building stronger collaborations with pharmaceutical innovators across the globe.
This will mark the third consecutive year that Samsung Biologics has taken part in BioJapan since its first appearance in 2023. However, the 2025 event is particularly notable because it represents the first time the company will operate an exclusive booth. Through this dedicated space, Samsung Biologics aims to take a more proactive role in engaging with leading pharmaceutical companies, forging new partnerships, and securing fresh business opportunities in one of the world’s most competitive healthcare markets.
At Booth D-105, the company will showcase its end-to-end biopharmaceutical development and manufacturing solutions, emphasizing the breadth and depth of its capabilities. Samsung Biologics operates the world’s largest biomanufacturing facilities and has earned recognition for its speed, flexibility, and high-quality service delivery. The company’s exhibit will focus on several key areas, including its antibody-drug conjugate (ADC) services, world-leading manufacturing capacity, and customized development platforms designed to support diverse therapeutic pipelines.
Key Presentations by Senior Executives
In addition to its booth presence, Samsung Biologics executives will take the stage on the first day of BioJapan to share insights into the company’s strategic direction and thought leadership in the biologics industry.
- James Choi, Executive Vice President and Head of Sales Support, will present a session titled “Strategic Outsourcing for Supply Chain Resilience”. This presentation will address the growing challenges faced by pharmaceutical and biotech companies in securing reliable supply chains, particularly in the wake of global disruptions such as the COVID-19 pandemic. Choi will emphasize how outsourcing to trusted partners like Samsung Biologics can help ensure resilience, reduce risk, and accelerate timelines in the development and commercialization of life-saving therapies.
- Kevin Sharp, Executive Vice President and Head of Sales & Operations, will deliver a presentation on “Integrating Biologics Development and Manufacturing for Diverse Modalities”. His session will highlight Samsung Biologics’ integrated approach to supporting a broad range of biologics, from monoclonal antibodies and ADCs to next-generation modalities such as bispecifics and fusion proteins. By streamlining development and manufacturing under one roof, the company aims to enable clients to bring complex therapies to market with greater efficiency and speed.
These sessions are expected to attract significant interest from attendees, offering valuable insights into how Samsung Biologics is addressing evolving industry needs while positioning itself as a trusted global partner.
Expanding Presence in Japan and the APAC Region
Samsung Biologics’ participation in BioJapan 2025 also underscores its strategic focus on strengthening its presence in the Asia-Pacific (APAC) region. Earlier this year, the company established a new sales office in Tokyo, signaling its long-term commitment to Japan—a market known for its strong pharmaceutical industry and advanced R&D ecosystem.
By setting up local operations, Samsung Biologics aims to enhance its accessibility to clients, foster closer relationships, and provide more timely support to Japanese pharmaceutical and biotech companies. The Tokyo office also serves as a regional hub to expand the company’s reach across APAC, where demand for high-quality biologics development and manufacturing continues to grow rapidly.
Driving Innovation and Collaboration
As the biopharmaceutical industry continues to evolve, demand for innovative solutions and reliable partnerships has never been greater. Samsung Biologics has consistently invested in cutting-edge technologies, sustainable operations, and talent development to meet these demands. The company’s decision to present its full range of services at BioJapan 2025 demonstrates its readiness to support clients throughout the entire biopharmaceutical lifecycle—from early development to large-scale commercial manufacturing.
The company’s emphasis on antibody-drug conjugates (ADCs) reflects its forward-looking approach. ADCs are widely considered one of the most promising therapeutic modalities for targeted cancer treatments. By offering specialized development and manufacturing services in this field, Samsung Biologics is positioning itself as a key partner for pharmaceutical companies seeking to develop next-generation oncology therapies.
